Athenex, Inc. – NASDAQ:ATNX

Financial Health
0
1
2
3
4
5
6
7
8
9

Athenex stock price monthly change

-83.76%
month

Athenex stock price quarterly change

-92.59%
quarter

Athenex stock price yearly change

-59.44%
year

Athenex key metrics

Market Cap
2.33M
Enterprise value
19.77M
P/E
-0.08
EV/Sales
0.19
EV/EBITDA
-0.26
Price/Sales
0.07
Price/Book
-1.20
PEG ratio
N/A
EPS
-16.17
Revenue
119.83M
EBITDA
-71.93M
Income
-102.88M
Revenue Q/Q
0.51%
Revenue Y/Y
-0.28%
Profit margin
-100.02%
Oper. margin
-68.52%
Gross margin
25.94%
EBIT margin
-68.52%
EBITDA margin
-60.03%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Athenex stock price history

Athenex stock forecast

Athenex financial statements

Athenex, Inc. (NASDAQ:ATNX): Profit margin
Mar 2022 29.72M -30.46M -102.51%
Jun 2022 31.51M -24.03M -76.26%
Sep 2022 33.53M -19.61M -58.5%
Dec 2022 25.06M -28.76M -114.78%
Athenex, Inc. (NASDAQ:ATNX): Earnings per share (EPS)
2023-05-15 -2.23 -4.8
Athenex, Inc. (NASDAQ:ATNX): Debt to assets
Mar 2022 236862000 216.06M 91.22%
Jun 2022 221887000 239.29M 107.85%
Sep 2022 228350000 221.11M 96.83%
Dec 2022 204055000 204.05M 100%
Athenex, Inc. (NASDAQ:ATNX): Cash Flow
Mar 2022 -23.88M 37.88M -25.37M
Jun 2022 -20.45M 8.32M 6.05M
Sep 2022 -16.27M -810K 20.78M
Dec 2022 -14.39M 12.50M 103K

Athenex alternative data

Athenex, Inc. (NASDAQ:ATNX): Employee count
Aug 2023 269
Sep 2023 269
Oct 2023 269
Nov 2023 269
Dec 2023 269
Jan 2024 269
Feb 2024 269
Mar 2024 269
Apr 2024 269
May 2024 269
Jun 2024 269
Jul 2024 269

Athenex other data

42.10% +9.79%
of ATNX is owned by hedge funds
47.57M +11.87M
shares is hold by hedge funds

Athenex, Inc. (NASDAQ:ATNX): Insider trades (number of shares)
Period Buy Sel
Sep 2021 50000 0
Oct 2021 10000 0
Nov 2021 62952 0
Aug 2022 20000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
ANNONI JOE officer: Chief Financial Officer
Restricted Stock Units 625 N/A N/A
Option
ANNONI JOE officer: Chief Financial Officer
Common Stock 625 N/A N/A
Option
COOK TIMOTHY DEVERE officer: Chief Business and Com..
Common Stock 2,250 N/A N/A
Option
LANG DANIEL officer: Pres Cell Therapy, VP ..
Restricted Stock Units 12,500 N/A N/A
Option
LANG DANIEL officer: Pres Cell Therapy, VP ..
Common Stock 12,500 N/A N/A
Option
COOK TIMOTHY DEVERE officer: Chief Business and Com..
Restricted Stock Units 2,250 N/A N/A
Purchase
LAU JOHNSON YIU NAM director, officer: CEO and Chai..
Common Stock 20,000 $0.46 $9,100
Option
KWAN RUDOLF officer: EVP, Chi.. Restricted Stock Units 17,500 N/A N/A
Option
LAU JOHNSON YIU NAM director, officer: CEO and Chai..
Restricted Stock Units 37,500 N/A N/A
Option
KWAN RUDOLF officer: EVP, Chi.. Common Stock 17,500 N/A N/A
Patent
Application
Filling date: 29 Sep 2021 Issue date: 26 May 2022
Application
Filling date: 31 Aug 2021 Issue date: 21 Apr 2022
Application
Filling date: 7 Oct 2021 Issue date: 7 Apr 2022
Application
Filling date: 7 Oct 2021 Issue date: 7 Apr 2022
Application
Filling date: 8 Dec 2020 Issue date: 11 Nov 2021
Application
Filling date: 19 Jan 2021 Issue date: 19 Aug 2021
Application
Filling date: 24 Aug 2020 Issue date: 15 Jul 2021
Application
Filling date: 17 Mar 2021 Issue date: 1 Jul 2021
Application
Filling date: 1 Mar 2021 Issue date: 1 Jul 2021
Grant
Filling date: 26 Dec 2018 Issue date: 13 Apr 2021
Insider Compensation
Mr. Jeffrey M. Yordon (1949) Chief Operating Officer & Pres of Athenex Pharmaceutical Division $693,450
Dr. Rudolf Kwan M.D., M.B., B.S. (1953) Chief Medical Officer $483,200
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. (1960) Chairman & Chief Executive Officer
$480,750
Monday, 15 May 2023
InvestorPlace
Thursday, 23 March 2023
Zacks Investment Research
Saturday, 4 February 2023
PennyStocks
Thursday, 5 January 2023
PennyStocks
Tuesday, 27 December 2022
PennyStocks
Friday, 23 December 2022
PennyStocks
Wednesday, 21 December 2022
PennyStocks
PennyStocks
Tuesday, 20 December 2022
InvestorPlace
Sunday, 6 November 2022
Seeking Alpha
Thursday, 3 November 2022
Zacks Investment Research
Tuesday, 6 September 2022
GlobeNewsWire
Friday, 5 August 2022
PennyStocks
Thursday, 28 July 2022
Seeking Alpha
Tuesday, 10 May 2022
Seeking Alpha
Monday, 2 May 2022
GlobeNewsWire
Wednesday, 16 March 2022
Seeking Alpha
Wednesday, 9 February 2022
GlobeNewsWire
Monday, 22 November 2021
Benzinga
Friday, 19 November 2021
Zacks Investment Research
Thursday, 18 November 2021
GlobeNewsWire
Sunday, 7 November 2021
Seeking Alpha
Thursday, 4 November 2021
Zacks Investment Research
Wednesday, 3 November 2021
Zacks Investment Research
Monday, 18 October 2021
GlobeNewsWire
Tuesday, 12 October 2021
Zacks Investment Research
Monday, 11 October 2021
GlobeNewsWire
Thursday, 16 September 2021
PennyStocks
Benzinga
GlobeNewsWire
  • When is Athenex's next earnings date?

    Unfortunately, Athenex's (ATNX) next earnings date is currently unknown.

  • Does Athenex pay dividends?

    No, Athenex does not pay dividends.

  • How much money does Athenex make?

    Athenex has a market capitalization of 2.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.44% to 102.82M US dollars. Athenex made a loss 98.98M US dollars in net income (profit) last year or -$4.8 on an earnings per share basis.

  • What is Athenex's stock symbol?

    Athenex, Inc. is traded on the NASDAQ under the ticker symbol "ATNX".

  • What is Athenex's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Athenex?

    Shares of Athenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Athenex's key executives?

    Athenex's management team includes the following people:

    • Mr. Jeffrey M. Yordon Chief Operating Officer & Pres of Athenex Pharmaceutical Division(age: 76, pay: $693,450)
    • Dr. Rudolf Kwan M.D., M.B., B.S. Chief Medical Officer(age: 72, pay: $483,200)
    • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. Chairman & Chief Executive Officer(age: 65, pay: $480,750)
  • How many employees does Athenex have?

    As Jul 2024, Athenex employs 269 workers.

  • When Athenex went public?

    Athenex, Inc. is publicly traded company for more then 8 years since IPO on 14 Jun 2017.

  • What is Athenex's official website?

    The official website for Athenex is athenex.com.

  • Where are Athenex's headquarters?

    Athenex is headquartered at Conventus Building, Buffalo, NY.

  • How can i contact Athenex?

    Athenex's mailing address is Conventus Building, Buffalo, NY and company can be reached via phone at +7 164272950.

Athenex company profile:

Athenex, Inc.

athenex.com
Exchange:

NASDAQ

Full time employees:

269

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Conventus Building
Buffalo, NY 14203

CIK: 0001300699
ISIN: US04685N1037
CUSIP: 04685N103